Artelo stock jumps 13% after FDA okays ART26.12 Phase 1 study

Stock Information for Artelo Biosciences Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Artelo Biosciences Inc.

Artelo Biosciences Provides Business Update and Reports First Quarter 2025 Financial Results
Artelo Biosciences Announces Publication of New Peer-Reviewed Research Demonstrating ART26.12's Effectiveness in Treating Psoriasis
Artelo Biosciences to Present Novel Scientific Insights for ART26.12 at the 4th ACE Drug Discovery Summit on April 3, 2025
Artelo Biosciences Provides Business Update and Reports Fiscal 2024 Year-End Financial Results
Artelo Biosciences Announces New Data on ART12.11 Tablets Showing Improved Pharmacokinetics to Epidiolex®
Artelo Biosciences to Present its New Data on ART12.11 Tablets Compared to Epidiolex at the IMCCB-25 Conference in Bern, Switzerland 
Artelo Biosciences Announces Successful Completion of First Cohort in a Phase 1 Study of ART26.12
Artelo Biosciences Announces Presentation of Phase 1 Data with ART27.13 in Cancer-Related Anorexia

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.